...TRPS received an undisclosed milestone payment from Chronogen under a 2004 deal in which TRPS uses...
...2004 deal in which TRPS uses its chemistry technology to provide drug discovery services to Chronogen...
...see BioCentury, Jan. 19, 2004). The payment was triggered by a program entering preclinical development. Chronogen Inc....

...Chronogen will begin this week an open-label Canadian Phase I/II trial in 24 healthy volunteers. Chronogen Inc....

...Bouchard, VP of clinical development and regulatory affairs at Labopharm Inc.; Max Felhmann, CEO of Chronogen...

...and lipid disorders. Chronogen will use its phenotype-based in vivo assays to screen Inpharzam's library. Chronogen Inc....

...which may be suitable for indications other than those for which they were originally developed. Chronogen Inc....